Sorafenib is the first and currently the only standard treatment for advanced hepatocellular
carcinoma (HCC). We previously developed a sorafenib derivative SC-43, which exhibits …

Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma
(HCC). Here, we report that Src homology region 2 (SH2) domain-containing phosphatase 1 …

Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma.
Here, we report that SC-60, a dimer-based sorafenib derivative, overcomes the resistance of …

Radiotherapy shows limited benefit as treatment for hepatocellular carcinoma (HCC). In this
study, we aimed to overcome the radioresistance of HCC by using a novel sorafenib …

BACKGROUND & AIMS: Recently, we reported that sorafenib sensitizes hepatocellular
carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of …

Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and
is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p …

Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a
small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical …

Background and Purpose Previously, we have shown that sorafenib sensitizes
hepatocellular carcinoma (HCC) to apoptosis induced by TNF‐related apoptosis‐inducing …

The multiple kinase inhibitor dovitinib is currently under clinical investigation for
hepatocellular carcinoma (HCC). Here, we investigated the mechanistic basis for the effects …

Signal transducer and activator of transcription 3 (STAT3) had been involved in liver
fibrogenesis. We aimed to explore the antifibrotic activities of sorafenib and its derivative SC …